Latest Conference Articles

Posters presented at the American Academy of Ophthalmology 2022 annual meeting show that the treat-and-extend (T&E) regimen was effective in managing neovascular age-related macular degeneration (nAMD), which makes adherence to treatment vital for long-term outcomes.

Advances in imaging and data science are changing the nature of retina practice, and retina specialists need to stay on top of these, said Michael F. Chiang, MD, director of the National Eye Institute (NEI), who also discussed some of the current research the agency is conducting into artificial intelligence (AI) and telemedicine.

Gene therapy can be used to treat retinitis pigmentosa, an inherited eye disease, and there is likely to be an increase in approved gene therapies for ophthalmic conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.

The presentation focused on the Protocol AC trial, which considered whether step therapy had an impact on visual outcomes for patients starting on bevacizumab and switching to aflibercept later.

The ophthalmology practice of the future will need to manage patients more efficiently and that means incorporating more technology, said Ravi Goel, MD, spokesperson for the AAO and ophthalmologist at Regional Eye Associates in New Jersey.

Posters presented at the American Academy of Ophthalmology 2022 annual meeting showed that patients with retinal vein occlusion (RVO) are most likely older with higher diastolic blood pressure, and they require prompt treatment to help manage the disease.

Speakers at a panel at the American Academy of Ophthalmology (AAO) 2022 conference spoke about future treatment options for patients in both minimally proven operations and in-office retina surgeries.

Ophthalmology is image heavy, which has made the specialty amenable to telemedicine and the implementation of artificial intelligence, said Grayson Armstrong, MD, medical director, ophthalmic emergency services at Massachusetts Eye and Ear, and instructor in ophthalmology at Harvard Medical School.

During the Parker Heath Lecture at the American Academy of Ophthalmology (AAO) annual meeting, James Madara, MD, CEO of the American Medical Association (AMA), will discuss the 3 arcs of the AMA’s strategic framework and the innovation that needs to occur.

The American Academy of Ophthalmology (AAO) will hold its conference in person in Chicago and online from September 30 to October 3, 2022.

During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.

SUNSHINE and SUNRISE trial data will be submitted to the FDA as part of Novartis’ Biologics License Application (BLA) for secukinumab in hidradenitis suppurativa.

Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial, currently evaluating the responses of treatment-naïve persons living with comorbid HIV/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.

Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.

The ALLIANCE trial is investigating the responses of treatment-naïve persons living with comorbid HIV (PLWH)/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.

Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.

Katherine R. Tuttle, MD, FASN, FACP, FNKF, a nephrologist from the University of Washington and Providence Health Care, discussed new consensus guidelines that call for the early use of sodium glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and finerenone in the care of patients with both chronic kidney disease (CKD) and diabetes.

Value management, theranostics, clinical trial access, and a mobile pharmacy are major innovations being integrated into independent community oncology practices, as highlighted at the Quality Cancer Care Alliance Summer 2022 National Leadership Summit.

Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial.

New heart failure guidelines redefine stages of the disease to emphasize prevention, said Biykem Bozkurt, MD, PhD, but more must be done by payers to identify those at high risk.

Coverage from the 2022 Congress of the American Society for Preventive Cardiology (ASPC) in Louisville, Kentucky, featuring 3 experts on aspects of hypertension treatment: Keith C. Ferdinand, MD, of Tulane University School of Medicine; Kim Allan Williams, MD, of the University of Louisville; and George C. Bakris, MD, of the University of Chicago Medicine.

Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial from Gilead.

During the 2022 Congress of the American Society for Preventive Cardiology (ASPC), held in Louisville, Kentucky, Erin D. Michos, MD, MHS, of Johns Hopkins, and Pam R. Taub, MD, of UC San Diego Health, discussed how treatment of diabetes requires going beyond glucose-lowering therapies and including newer medications that offer cardiovascular benefits.

Martha Gulati, MD, MS, kicked off the symposium “Saving the Hearts of Women Through Prevention” ahead of the 2022 Congress of the American Society for Preventive Cardiology, which took place Friday through Sunday in Louisville, Kentucky.

Social determinants of health are major drivers of the inequities seen in health outcomes, and racism is clearly a social determinant tied to life expectancy, said Karol Watson, MD, PhD, in talk Sunday at the 2022 Congress of the American Society for Preventive Cardiology, held in Louisville, Kentucky.

Ty J. Gluckman, MD, FACC, FAHA, who is medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, addressed the 2022 Congress of the American Society for Preventive Cardiology meeting in Louisville, Kentucky.

Duke University’s Pamela S. Douglas, MD, spoke to cardiology professionals who gathered for the start of the 2022 Congress of the American Society for Preventive Cardiology (ASPC), in Louisville, Kentucky.

The ALLIANCE trial is the first randomized blinded trial to investigate tenofovir alafenamide vs tenofovir disoproxil fumarate in treatment-naive individuals who have comorbid HIV/hepatitis B virus (HBV) infection.